2,5-Dihydro-[1,2,4]triazino[6,5-b][1,4]benzothiazine-3-thione

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2,5-Dihydro-[1,2,4]triazino[6,5-b][1,4]benzothiazine-3-thione
• 化学式: C₉H₆N₄S₂
• 分子量: 234.3
• InChiKey: GBFLHKGGDMKJII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] MIR-122 AGONIST<br/>[FR] AGONISTE DE MIR-22
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2009091982A1

  公开（公告）日：2009-07-23

  This invention relates generally to chemically modified oligonuceotides useful for augmenting activity of microRNAs and pre-microRNAs. E.g., the invention relates to single stranded chemically modified oligonuceotides for augmenting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides.
• [EN] CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF<br/>[FR] OLIGONUCLÉOTIDES MODIFIÉS CHIMIQUEMENT ET PETITES MOLÉCULES À UTILISER DANS LA RÉDUCTION DES TAUX D'ACTIVITÉ DE MICROARN ET LEURS UTILISATIONS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2009091972A2

  公开（公告）日：2009-07-23

  This invention relates generally to chemically modified oligonuceotides useful for modulating activity of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA activity and to methods of making and using the modified oligonucleotides.
• [EN] REVERSIRTM COMPOUNDS<br/>[FR] COMPOSÉS REVERSIRTM
  申请人：JADHAV VASANT

  公开号：WO2016100716A1

  公开（公告）日：2016-06-23

  The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs.
• [EN] TUNABLE REVERSIR TM COMPOUNDS<br/>[FR] COMPOSÉS REVERSIR TM RÉGLABLES
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2019036612A1

  公开（公告）日：2019-02-21

  The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.